Purple Biotech Ltd (TLV:PPBT)
Israel
· Delayed Price · Currency is ILS · Price in ILA 5.30
+0.20 (3.92%)
Apr 2, 2025, 3:40 PM IDT
Purple Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 7.4 | 14.49 | 15.03 | 10.89 | 11.25 | Upgrade
|
| Short-Term Investments | 1.12 | 0.92 | 17.08 | 36.31 | 46.56 | Upgrade
|
| Cash & Short-Term Investments | 8.52 | 15.41 | 32.11 | 47.2 | 57.81 | Upgrade
|
| Cash Growth | -44.69% | -52.01% | -31.96% | -18.35% | 1215.24% | Upgrade
|
| Accounts Receivable | - | - | - | - | 0.5 | Upgrade
|
| Receivables | - | - | - | - | 0.5 | Upgrade
|
| Prepaid Expenses | 0.28 | 0.21 | 1 | 1.01 | 0.78 | Upgrade
|
| Other Current Assets | 0.11 | 0.17 | 0.15 | 0.27 | 0.2 | Upgrade
|
| Total Current Assets | 8.91 | 15.79 | 33.26 | 48.47 | 59.28 | Upgrade
|
| Property, Plant & Equipment | 0.29 | 0.47 | 0.68 | 0.9 | 0.97 | Upgrade
|
| Long-Term Investments | - | - | - | 0.19 | - | Upgrade
|
| Other Intangible Assets | 27.84 | 28.04 | 20.68 | 20.48 | 20.48 | Upgrade
|
| Other Long-Term Assets | - | - | - | 0.16 | 3.07 | Upgrade
|
| Total Assets | 37.04 | 44.3 | 54.62 | 70.2 | 83.8 | Upgrade
|
| Accounts Payable | 1.46 | 3.53 | 2.13 | 1.47 | 1.2 | Upgrade
|
| Accrued Expenses | 1.2 | 3.46 | 4.72 | 2.56 | 1.69 | Upgrade
|
| Current Portion of Leases | 0.18 | 0.19 | 0.19 | 0.2 | 0.21 | Upgrade
|
| Other Current Liabilities | 1.15 | 2.52 | 0.01 | 0.02 | - | Upgrade
|
| Total Current Liabilities | 3.99 | 9.7 | 7.06 | 4.25 | 3.1 | Upgrade
|
| Long-Term Leases | - | 0.16 | 0.32 | 0.55 | 0.69 | Upgrade
|
| Total Liabilities | 4.13 | 10.01 | 7.52 | 5.09 | 4.05 | Upgrade
|
| Additional Paid-In Capital | 147.63 | 133.18 | 126.41 | 123.95 | 118.91 | Upgrade
|
| Retained Earnings | -144.69 | -137.45 | -117.57 | -95.91 | -77.52 | Upgrade
|
| Comprehensive Income & Other | 29.92 | 38.48 | 38.08 | 36.78 | 38 | Upgrade
|
| Total Common Equity | 32.86 | 34.21 | 46.91 | 64.83 | 79.39 | Upgrade
|
| Minority Interest | 0.05 | 0.09 | 0.19 | 0.28 | 0.36 | Upgrade
|
| Shareholders' Equity | 32.91 | 34.3 | 47.1 | 65.11 | 79.75 | Upgrade
|
| Total Liabilities & Equity | 37.04 | 44.3 | 54.62 | 70.2 | 83.8 | Upgrade
|
| Total Debt | 0.18 | 0.35 | 0.52 | 0.75 | 0.9 | Upgrade
|
| Net Cash (Debt) | 8.34 | 15.06 | 31.6 | 46.45 | 56.91 | Upgrade
|
| Net Cash Growth | -44.62% | -52.34% | -31.98% | -18.38% | 1264.09% | Upgrade
|
| Net Cash Per Share | 0.03 | 0.07 | 0.17 | 0.26 | 0.49 | Upgrade
|
| Filing Date Shares Outstanding | 529.64 | 265.58 | 207.87 | 178.26 | 175.11 | Upgrade
|
| Total Common Shares Outstanding | 517.13 | 252.38 | 184.82 | 178 | 172.11 | Upgrade
|
| Working Capital | 4.92 | 6.09 | 26.2 | 44.22 | 56.18 | Upgrade
|
| Book Value Per Share | 0.06 | 0.14 | 0.25 | 0.36 | 0.46 | Upgrade
|
| Tangible Book Value | 5.02 | 6.16 | 26.23 | 44.35 | 58.91 | Upgrade
|
| Tangible Book Value Per Share | 0.01 | 0.02 | 0.14 | 0.25 | 0.34 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.